Are you Dr. Tozbikian?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 27 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
410 W 10th Ave E419
Columbus, OH 43210Phone+1 614-293-5905Fax+1 614-293-4715- Is this information wrong?
Summary
- Dr. Gary Tozbikian, MD is a board certified pathologist in Columbus, Ohio. He is currently licensed to practice medicine in Ohio and Pennsylvania. He is affiliated with The OSUCCC - James, Ohio State University Wexner Medical Center, and Chillicothe Veterans Affairs Medical Center.
Education & Training
- University of Pennsylvania Health System GI/Hepatic PathologyFellowship, Selective Pathology, 2011 - 2012
- University of Pennsylvania Health SystemResidency, Pathology-Anatomic and Clinical, 2007 - 2011
- Ohio State University College of MedicineClass of 2007
Certifications & Licensure
- OH State Medical License 2013 - 2025
- PA State Medical License 2007 - 2012
- American Board of Pathology Pathology - Anatomic/Pathology - Clinical
Publications & Presentations
PubMed
- 2 citationsAnalytical and clinical validation of PATHWAY Anti-HER-2/neu (4B5) antibody to assess HER2-low status for trastuzumab deruxtecan treatment in breast cancer.Charo Garrido, Melissa Manoogian, Dhiraj Ghambire, Shawn Lucas, Maha Karnoub, Matthew T Olson, David G Hicks, Gary Tozbikian, Aleix Prat, Naoto T Ueno, Shanu Modi, Wen...> ;Virchows Archiv. 2023 Oct 20
- Survival outcomes seen with neoadjuvant chemotherapy in the management of locally advanced inflammatory breast cancer (IBC) versus matched controls.Kai Cc Johnson, Michael Grimm, Jasmine Sukumar, Patrick M Schnell, Ko Un Park, Daniel G Stover, Sachin R Jhawar, Margaret Gatti-Mays, Robert Wesolowski, Nicole William...> ;Breast. 2023 Dec 1
- The Significance of Recognition of Human Epidermal Growth Factor 2 Low in Breast Cancer Therapy.Gary Tozbikian> ;Advances in Anatomic Pathology. 2023 Nov 1
- Join now to see all
Press Mentions
- PD-L1 Testing in Triple-Negative Breast Cancer: Post Hoc IMpassion130 Substudy Evaluates PD-L1 IHC Assay PerformanceApril 1st, 2020
Hospital Affiliations
- Ohio State University Wexner Medical CenterColumbus, Ohio
- The OSUCCC - JamesColumbus, Ohio
- Chillicothe Veterans Affairs Medical CenterChillicothe, Ohio